BioCardia (BCDA) Change in Account Payables (2016 - 2026)
BioCardia's (BCDA) quarterly Change in Account Payables came in at -$255000.0 in Q2 2026, down 179.94% year-over-year from $319000.0 in Q2 2025, and down 203.24% quarter-over-quarter from $247000.0 in Q1 2026.
Powered by 
Analysis
BioCardia (BCDA) Change in Account Payables (2016 - 2026) Analysis & Trends
BioCardia (BCDA) has reported Change in Account Payables for 11 consecutive years, with -$255000.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Change in Account Payables fell 179.94% year-over-year to -$255000.0 in Q2 2026; TTM through Jun 2026 was -$586000.0, a 330.88% decrease from a year earlier, with the FY2025 full-year figure at $163000.0, up 151.58% from the prior year.
- Change in Account Payables was -$255000.0 for Q2 2026 at BioCardia, down from $247000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $422000.0 in Q1 2025 and troughed at -$726000.0 in Q3 2024.
- A 5-year average of $1500.0 and a median of $55000.0 in 2022 frame the typical range for Change in Account Payables.
- The widest YoY moves for Change in Account Payables: up 247.1% in 2024, down 680.65% in 2024.
- Over 5 years, Change in Account Payables stood at -$376000.0 in 2022, then jumped by 155.32% to $208000.0 in 2023, then sank by 172.6% to -$151000.0 in 2024, then plunged by 141.72% to -$365000.0 in 2025, then jumped by 30.14% to -$255000.0 in 2026.
- The last three Change in Account Payables figures came in at -$255000.0 (Q2 2026), $247000.0 (Q1 2026), and -$365000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn | 3.06 Mn |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn | -11.82 Mn |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | 2.90 Mn |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | 625,000.00 |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - | 1.21 Mn |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn | 2.84 Mn |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn | -19.39 Mn |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn | 1.57 Mn |
| 10 | BioCardia | 13.06 Mn | 8.94 Mn | - | -255,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -255,000.00 |
| Mar 31, 2026 | 247,000.00 |
| Dec 31, 2025 | -365,000.00 |
| Sep 30, 2025 | -213,000.00 |
| Jun 30, 2025 | 319,000.00 |
| Mar 31, 2025 | 422,000.00 |
| Dec 31, 2024 | -151,000.00 |
| Sep 30, 2024 | -726,000.00 |
| Jun 30, 2024 | 406,000.00 |
| Mar 31, 2024 | 155,000.00 |
| Dec 31, 2023 | 208,000.00 |
| Sep 30, 2023 | -93,000.00 |
| Jun 30, 2023 | -276,000.00 |
| Mar 31, 2023 | 345,000.00 |
| Dec 31, 2022 | -376,000.00 |
| Sep 30, 2022 | -45,000.00 |
| Jun 30, 2022 | 168,000.00 |
| Mar 31, 2022 | 257,000.00 |
| Dec 31, 2021 | -339,000.00 |
| Sep 30, 2021 | -110,000.00 |